Mayank Dhalani
Research Subjects
Mayank Dhalani has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Rohit Jain
Department of Medicine Miller School of Medicine University of Miami FL USA
3 shared publications- Rohit Jain
Penn State Milton S. Hershey Medical Center
2 shared publications Abhinav Malik
1 shared publication- Arihant Senthil
University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India
1 shared publication - Bhupinder Singh
Government Medical College, Amritsar, India
1 shared publication - Dharti Dua
Ohio State University Wexner Medical Center, Columbus, OH; and
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 8, 121-136
Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies
Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage.Methods: This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies.Results: Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation.Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.
- 29 July 2026
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 8, 121-136
Open AccessAdvances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies
Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage.Methods: This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies.Results: Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation.Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.
- 17 February 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (2) , 136-145
Cystatin C in chronic kidney disease: enhancing diagnostic accuracy and patient outcomes
- 17 February 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (2) , 136-145
Cystatin C in chronic kidney disease: enhancing diagnostic accuracy and patient outcomes
- Open Access
- 7 August 2025
- Published by Mansa STM Publishers in Eastern Journal of Medical Sciences
- Vol. 10 (2) , 17-25
Long-Term Impact of Oral Contraceptive Use in Adult Life on Postmenopausal Hypertension
Oral contraceptive pills (OCP) are widely utilized globally for both contraceptive and non-contraceptive purposes, with combined oral contraceptive pills being the more commonly prescribed type compared to progestin-only pills. Despite their efficacy, OCPs are associated with various adverse effects, including the development of hypertension. Hypertension, a prevalent condition among older women, particularly those over 60 years of age, has been linked to prior OCP use, potentially contributing to an elevated risk of cardiovascular and cerebrovascular disorders. The mechanisms underlying OCP-induced hypertension include activation of the renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction, vascular remodeling, inflammation, and oxidative stress. Evidence suggests that estrogen-containing OCPs can exert long-term effects on blood pressure regulation, increasing the likelihood of hypertension, particularly with prolonged use or higher estrogen doses. However, newer formulations with lower estrogen doses have been shown to mitigate this risk. Additionally, certain progestins, such as drospirenone, may exert protective effects by reducing blood pressure. Ongoing research and vigilant monitoring are essential to further elucidate these associations and optimize OCP formulations for safer use.
- 7 August 2025
- Published by Mansa STM Publishers in Eastern Journal of Medical Sciences
- Vol. 10 (2) , 17-25
Open AccessLong-Term Impact of Oral Contraceptive Use in Adult Life on Postmenopausal Hypertension
Oral contraceptive pills (OCP) are widely utilized globally for both contraceptive and non-contraceptive purposes, with combined oral contraceptive pills being the more commonly prescribed type compared to progestin-only pills. Despite their efficacy, OCPs are associated with various adverse effects, including the development of hypertension. Hypertension, a prevalent condition among older women, particularly those over 60 years of age, has been linked to prior OCP use, potentially contributing to an elevated risk of cardiovascular and cerebrovascular disorders. The mechanisms underlying OCP-induced hypertension include activation of the renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction, vascular remodeling, inflammation, and oxidative stress. Evidence suggests that estrogen-containing OCPs can exert long-term effects on blood pressure regulation, increasing the likelihood of hypertension, particularly with prolonged use or higher estrogen doses. However, newer formulations with lower estrogen doses have been shown to mitigate this risk. Additionally, certain progestins, such as drospirenone, may exert protective effects by reducing blood pressure. Ongoing research and vigilant monitoring are essential to further elucidate these associations and optimize OCP formulations for safer use.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 21 (2) , 1-8
Elevated Perspectives: Unraveling Cardiovascular Dynamics in High-Altitude Realms
High-altitude regions pose distinctive challenges for cardiovascular health because of decreased oxygen levels, reduced barometric pressure, and colder temperatures. Approximately 82 million people live above 2400 meters, while over 100 million people visit these heights annually. Individuals ascending rapidly or those with pre-existing cardiovascular conditions are particularly vulnerable to altitude-related illnesses, including Acute Mountain Sickness (AMS) and Chronic Mountain Sickness (CMS). The cardiovascular system struggles to adapt to hypoxic stress, which can lead to arrhythmias, systemic hypertension, and right ventricular failure. Pathophysiologically, high-altitude exposure triggers immediate increases in cardiac output and heart rate, often due to enhanced sympathetic activity. Over time, acclimatisation involves complex changes, such as reduced stroke volume and increased blood volume. The pulmonary vasculature also undergoes significant alterations, including hypoxic pulmonary vasoconstriction and vascular remodelling, contributing to conditions, like pulmonary hypertension and high-altitude pulmonary edema. Genetic adaptations in populations living at high altitudes, such as gene variations linked to hypoxia response, further influence these physiological processes. Regarding cardiovascular disease risk, stable coronary artery disease patients generally do not face significant adverse outcomes at altitudes up to 3500 meters. However, those with unstable angina or recent cardiac interventions should avoid high-altitude exposure to prevent exacerbation. Remarkably, high-altitude living correlates with reduced cardiovascular mortality rates, possibly due to improved air quality and hypoxia-induced adaptations. Additionally, there is a higher incidence of congenital heart disease among children born at high altitudes, highlighting the profound impact of hypoxia on heart development. Understanding these dynamics is crucial for managing risks and improving health outcomes in high-altitude environments.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 21 (2) , 1-8
Elevated Perspectives: Unraveling Cardiovascular Dynamics in High-Altitude Realms
High-altitude regions pose distinctive challenges for cardiovascular health because of decreased oxygen levels, reduced barometric pressure, and colder temperatures. Approximately 82 million people live above 2400 meters, while over 100 million people visit these heights annually. Individuals ascending rapidly or those with pre-existing cardiovascular conditions are particularly vulnerable to altitude-related illnesses, including Acute Mountain Sickness (AMS) and Chronic Mountain Sickness (CMS). The cardiovascular system struggles to adapt to hypoxic stress, which can lead to arrhythmias, systemic hypertension, and right ventricular failure. Pathophysiologically, high-altitude exposure triggers immediate increases in cardiac output and heart rate, often due to enhanced sympathetic activity. Over time, acclimatisation involves complex changes, such as reduced stroke volume and increased blood volume. The pulmonary vasculature also undergoes significant alterations, including hypoxic pulmonary vasoconstriction and vascular remodelling, contributing to conditions, like pulmonary hypertension and high-altitude pulmonary edema. Genetic adaptations in populations living at high altitudes, such as gene variations linked to hypoxia response, further influence these physiological processes. Regarding cardiovascular disease risk, stable coronary artery disease patients generally do not face significant adverse outcomes at altitudes up to 3500 meters. However, those with unstable angina or recent cardiac interventions should avoid high-altitude exposure to prevent exacerbation. Remarkably, high-altitude living correlates with reduced cardiovascular mortality rates, possibly due to improved air quality and hypoxia-induced adaptations. Additionally, there is a higher incidence of congenital heart disease among children born at high altitudes, highlighting the profound impact of hypoxia on heart development. Understanding these dynamics is crucial for managing risks and improving health outcomes in high-altitude environments.
- Open Access
- 29 January 2025
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 7 (1) , 1-11
Exploring the Silent Connection Between Sleep Disorders (i.e., OSA, Insomnia) and Cardiovascular Diseases: Pathophysiology and Insights
Sleep is a complex physiological phenomenon crucial for health. Despite this, millions suffer from sleep disorders, contributing to a range of health issues, particularly cardiovascular diseases (CVD). The pathophysiological mechanisms linking sleep disorders, such as insomnia and obstructive sleep apnea (OSA), to cardiovascular risk factors include disruptions in inflammatory, autonomic, and metabolic pathways. Increased sympathetic nervous system activity, chronic inflammation, and metabolic dysregulation stemming from poor sleep can lead to conditions like hypertension, obesity, and insulin resistance, significantly elevating the risk for CVD. This article reviews the connection between sleep quality and cardiovascular disease risks. Sleep disorders (i.e., insomnia and OSA) have been found to impact cardiovascular risk factors adversely. Studies have found an association between abnormal sleep and increased cardiovascular morbidity and mortality by higher risks of hypertension, diabetes, obesity, and dyslipidemia. The review also discusses non-pharmacological interventions, such as relaxation training, Cognitive behavioral therapy for insomnia (CBT-I), and red-light therapy, which have shown efficacy in improving sleep quality and reducing cardiovascular risks. Dual orexin receptor antagonists and Ashwagandha promise to enhance sleep quality and cardiovascular health, but further research is needed. Addressing sleep disorders and promoting healthy sleep practices are essential for mitigating the global burden of cardiovascular diseases, underscoring the need for continued research and effective public health interventions.
- 29 January 2025
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 7 (1) , 1-11
Open AccessExploring the Silent Connection Between Sleep Disorders (i.e., OSA, Insomnia) and Cardiovascular Diseases: Pathophysiology and Insights
Sleep is a complex physiological phenomenon crucial for health. Despite this, millions suffer from sleep disorders, contributing to a range of health issues, particularly cardiovascular diseases (CVD). The pathophysiological mechanisms linking sleep disorders, such as insomnia and obstructive sleep apnea (OSA), to cardiovascular risk factors include disruptions in inflammatory, autonomic, and metabolic pathways. Increased sympathetic nervous system activity, chronic inflammation, and metabolic dysregulation stemming from poor sleep can lead to conditions like hypertension, obesity, and insulin resistance, significantly elevating the risk for CVD. This article reviews the connection between sleep quality and cardiovascular disease risks. Sleep disorders (i.e., insomnia and OSA) have been found to impact cardiovascular risk factors adversely. Studies have found an association between abnormal sleep and increased cardiovascular morbidity and mortality by higher risks of hypertension, diabetes, obesity, and dyslipidemia. The review also discusses non-pharmacological interventions, such as relaxation training, Cognitive behavioral therapy for insomnia (CBT-I), and red-light therapy, which have shown efficacy in improving sleep quality and reducing cardiovascular risks. Dual orexin receptor antagonists and Ashwagandha promise to enhance sleep quality and cardiovascular health, but further research is needed. Addressing sleep disorders and promoting healthy sleep practices are essential for mitigating the global burden of cardiovascular diseases, underscoring the need for continued research and effective public health interventions.
- 1 February 2024
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 34 (1) , 40-46
The Synergy of Percutaneous Coronary Intervention and Lifestyle Modification in Reducing Mortality and Blockage Prevention
In developed countries, cardiovascular diseases are the leading cause of death. Cardiovascular disease risk factors can be categorized as non modifiable (age, sex, race, and family history) or modifiable (hypertension, hyperlipidemia, diabetes, obesity, smoking, poor nutrition, stress, and sedentary lifestyle). Over 50% of cardiovascular events and deaths can be attributed to modifiable risk factors. The American Heart Association developed the “Life’s Simple 7” framework, which illustrates how lifestyle modifications—such as increasing physical activity, improving diet, giving up smoking, and managing weight—can contribute to heart-healthy living. Cardiac rehabilitation programs target these lifestyle modifications and result in a 35% reduction in 5-year mortality after myocardial infarction or bypass surgery. By promoting cardiac preconditioning, increasing coronary collateralization, and plaque regression, among other processes, physical exercise lowers the risk of cardiovascular death. It has been demonstrated that various diets, such as those high in fiber, low in saturated fats, low in sodium, and high in potassium, can reduce the risk of cardiovascular disease. Smoking destroys the vascular endothelium and produces free radicals, which trigger the start and advancement of atherosclerosis. Quitting smoking decreased cardiovascular mortality by 39% in one of the studies. Cognitive-behavioral treatment for depression and other psycho-behavioral and emotional therapies have been demonstrated to enhance heart function and lower the incidence of unfavorable cardiovascular events. Therefore, by following heart-healthy eating habits, getting regular exercise, giving up smoking, and controlling their stress, people can improve their quality of life and make their percutaneous coronary intervention operation more successful in the long run. This article addresses the above 4 lifestyle modalities, their pathophysiology, and their impact on cardiovascular outcomes post percutaneous interventions.
- 1 February 2024
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 34 (1) , 40-46
The Synergy of Percutaneous Coronary Intervention and Lifestyle Modification in Reducing Mortality and Blockage Prevention
In developed countries, cardiovascular diseases are the leading cause of death. Cardiovascular disease risk factors can be categorized as non modifiable (age, sex, race, and family history) or modifiable (hypertension, hyperlipidemia, diabetes, obesity, smoking, poor nutrition, stress, and sedentary lifestyle). Over 50% of cardiovascular events and deaths can be attributed to modifiable risk factors. The American Heart Association developed the “Life’s Simple 7” framework, which illustrates how lifestyle modifications—such as increasing physical activity, improving diet, giving up smoking, and managing weight—can contribute to heart-healthy living. Cardiac rehabilitation programs target these lifestyle modifications and result in a 35% reduction in 5-year mortality after myocardial infarction or bypass surgery. By promoting cardiac preconditioning, increasing coronary collateralization, and plaque regression, among other processes, physical exercise lowers the risk of cardiovascular death. It has been demonstrated that various diets, such as those high in fiber, low in saturated fats, low in sodium, and high in potassium, can reduce the risk of cardiovascular disease. Smoking destroys the vascular endothelium and produces free radicals, which trigger the start and advancement of atherosclerosis. Quitting smoking decreased cardiovascular mortality by 39% in one of the studies. Cognitive-behavioral treatment for depression and other psycho-behavioral and emotional therapies have been demonstrated to enhance heart function and lower the incidence of unfavorable cardiovascular events. Therefore, by following heart-healthy eating habits, getting regular exercise, giving up smoking, and controlling their stress, people can improve their quality of life and make their percutaneous coronary intervention operation more successful in the long run. This article addresses the above 4 lifestyle modalities, their pathophysiology, and their impact on cardiovascular outcomes post percutaneous interventions.